Sonoma Historical Cash Flow
| SNOA Stock | USD 2.92 0.01 0.34% |
Analysis of Sonoma Pharmaceuticals cash flow over time is an excellent tool to project Sonoma Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Depreciation of 298.9 K or Other Non Cash Items of 169.1 K as it is a great indicator of Sonoma Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Sonoma Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Sonoma Pharmaceuticals is a good buy for the upcoming year.
Sonoma |
About Sonoma Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Sonoma balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Sonoma's non-liquid assets can be easily converted into cash.
Sonoma Pharmaceuticals Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Sonoma Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Sonoma Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Sonoma Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Sonoma Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonoma Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.At present, Sonoma Pharmaceuticals' Change In Working Capital is projected to increase significantly based on the last few years of reporting. The current year's Begin Period Cash Flow is expected to grow to about 5.6 M, whereas Sale Purchase Of Stock is forecasted to decline to about 3.2 M.
Sonoma Pharmaceuticals cash flow statement Correlations
Click cells to compare fundamentals
Sonoma Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sonoma Pharmaceuticals cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Sale Purchase Of Stock | 5.5M | 6.0M | 1.4M | 3.6M | 3.2M | 3.2M | |
| Change In Cash | 2K | 529K | 3.2M | (3.6M) | (692K) | (657.4K) | |
| Free Cash Flow | (4.8M) | (3.6M) | (4.4M) | (6.4M) | (2.4M) | (2.5M) | |
| Change In Working Capital | (2.0M) | 1.4M | 3.1M | (1.9M) | 1.7M | 1.8M | |
| Other Cashflows From Financing Activities | 1.0M | 388K | 7.9M | 2.6M | 373K | 354.4K | |
| Depreciation | 312K | 227K | 186K | 125K | 176K | 298.9K | |
| Other Non Cash Items | 464K | 4K | (2.0M) | 106K | 161K | 169.1K | |
| Capital Expenditures | 206K | 179K | 137K | 269K | 17K | 16.2K | |
| Total Cash From Operating Activities | (4.6M) | (3.4M) | (4.2M) | (6.2M) | (2.4M) | (2.5M) | |
| Net Income | (2.9M) | (4.0M) | (5.1M) | (5.2M) | (4.8M) | (5.1M) | |
| Total Cash From Financing Activities | 1.0M | 3.3M | 7.4M | 2.5M | 1.7M | 1.6M | |
| End Period Cash Flow | 3.7M | 4.2M | 7.4M | 3.8M | 3.1M | 5.7M | |
| Change To Inventory | 323K | (65K) | (100K) | 44K | 184K | 193.2K | |
| Stock Based Compensation | 839K | 371K | 382K | 669K | 516K | 490.2K | |
| Change To Account Receivables | (2.2M) | 2.6M | 2.0M | 62K | (230K) | (218.5K) | |
| Other Cashflows From Investing Activities | 3.9M | 567K | 38K | 11K | 12.7K | 12.0K | |
| Total Cashflows From Investing Activities | 3.6M | 388K | (99K) | (258K) | (232.2K) | (220.6K) | |
| Investments | 3.6M | 388K | (99K) | (258K) | (2K) | (1.9K) | |
| Change Receivables | 11K | (1.2M) | (2.2M) | 2.6M | 3.0M | 3.1M | |
| Net Borrowings | (347K) | 1.0M | (374K) | (379K) | (435.9K) | (457.6K) | |
| Exchange Rate Changes | 5K | (21K) | (80K) | 211K | 242.7K | 254.8K | |
| Cash And Cash Equivalents Changes | (7.4M) | (6.4M) | 2K | 529K | 476.1K | 499.9K | |
| Cash Flows Other Operating | (240K) | (123K) | 918K | 564K | 648.6K | 681.0K | |
| Change To Operating Activities | (395K) | (745K) | 157K | (162K) | (145.8K) | (138.5K) | |
| Change To Netincome | (1.2M) | (1.0M) | (2.5M) | 738K | 848.7K | 891.1K | |
| Change To Liabilities | 177K | (811K) | 743K | (2.2M) | (2.5M) | (2.4M) | |
| Issuance Of Capital Stock | 1.4M | 6.9M | 7.6M | 2.9M | 1.8M | 3.5M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sonoma Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonoma Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonoma Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonoma Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonoma Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonoma Pharmaceuticals. If investors know Sonoma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonoma Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.99) | Revenue Per Share 20.967 | Quarterly Revenue Growth (0.01) | Return On Assets (0.20) | Return On Equity (0.75) |
The market value of Sonoma Pharmaceuticals is measured differently than its book value, which is the value of Sonoma that is recorded on the company's balance sheet. Investors also form their own opinion of Sonoma Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Sonoma Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonoma Pharmaceuticals' market value can be influenced by many factors that don't directly affect Sonoma Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonoma Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonoma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonoma Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.